39781498|t|Olanzapine versus quetiapine in critically ill patients with hyperactive delirium: Protocol for a multicentre, cluster-randomised, double-crossover, pragmatic clinical trial (CALM-ICU).
39781498|a|Background: Patients in the intensive care unit (ICU) frequently develop hyperactive delirium, which may be accompanied by behaviour that increases clinical risks to themselves as well as other patients and staff. There is a paucity of evidence to inform the urgent enteral administration of antipsychotic drugs to treat such hyperactive delirium and behavioural disturbances. Objective: The aim of this study is to test the efficacy and safety of administering enteral olanzapine when compared to quetiapine in critically ill patients with hyperactive delirium. Design setting participants and interventions: This is a cluster-randomised, double-crossover, clinical trial. Critically ill adult patients admitted to three tertiary Australian intensive care units over a 12-month period will be eligible. Randomisation will occur at the site level, with allocation to open-label olanzapine or quetiapine use over four treatment periods of 3-month duration. Main outcome measure: The primary outcome and days alive and delirium-/coma-free (censored at 14 days post enrolment) will be analysed using median quantile regression accounting for clustering at sites' level and time period and treatment order. Results and conclusion: This trial will compare the effect of enteral olanzapine to quetiapine in critically ill adults with hyperactive delirium on an important indicator of patient outcome.
39781498	0	10	Olanzapine	Chemical	MESH:D000077152
39781498	18	28	quetiapine	Chemical	MESH:D000069348
39781498	32	46	critically ill	Disease	MESH:D016638
39781498	47	55	patients	Species	9606
39781498	61	81	hyperactive delirium	Disease	MESH:D003693
39781498	198	206	Patients	Species	9606
39781498	259	279	hyperactive delirium	Disease	MESH:D003693
39781498	380	388	patients	Species	9606
39781498	512	532	hyperactive delirium	Disease	MESH:D003693
39781498	537	561	behavioural disturbances	Disease	MESH:D014832
39781498	656	666	olanzapine	Chemical	MESH:D000077152
39781498	684	694	quetiapine	Chemical	MESH:D000069348
39781498	698	712	critically ill	Disease	MESH:D016638
39781498	713	721	patients	Species	9606
39781498	727	747	hyperactive delirium	Disease	MESH:D003693
39781498	764	776	participants	Species	9606
39781498	860	874	Critically ill	Disease	MESH:D016638
39781498	881	889	patients	Species	9606
39781498	1064	1074	olanzapine	Chemical	MESH:D000077152
39781498	1078	1088	quetiapine	Chemical	MESH:D000069348
39781498	1203	1211	delirium	Disease	MESH:D003693
39781498	1213	1217	coma	Disease	MESH:D003128
39781498	1459	1469	olanzapine	Chemical	MESH:D000077152
39781498	1473	1483	quetiapine	Chemical	MESH:D000069348
39781498	1487	1501	critically ill	Disease	MESH:D016638
39781498	1514	1534	hyperactive delirium	Disease	MESH:D003693
39781498	1564	1571	patient	Species	9606
39781498	Negative_Correlation	MESH:D000077152	MESH:D016638
39781498	Negative_Correlation	MESH:D000069348	MESH:D016638
39781498	Comparison	MESH:D000069348	MESH:D000077152
39781498	Negative_Correlation	MESH:D000069348	MESH:D003693
39781498	Negative_Correlation	MESH:D000077152	MESH:D003693

